Introduction:

Lung cancer is the leading cause of cancer death worldwide, showing an increase in women and non-smokers in the last decade. Progress in the diagnostic-therapeutic approach has been achieved thanks to the knowledge of tumor heterogeneity and molecular analysis.

Material and methods:

The base of patients with lung cancer was analyzed from January 2013 to June 2018, with registration of sociodemographic, clinical and molecular profile variables. Results expressed through measures of central tendency and crude odd ratio was estimated for EGFR mutation and exposure antecedent and its statistical significance by Fisher’s exact test.

Results:

A cohort analyzed from January 2013 to June 2018 with 751 patients. The average age was 62.2 years, 53% (n = 398) were female, 51.8% (n = 389) were never smokers. The most common symptoms were cough in 87.1% and dyspnea in 74.4%. The bronchoscopic procedure was the preferred diagnostic method. Clinical stage IV was the most frequently reported. EGFR was positive in 38.19% of NSCLC.

Conclusion:

The clinical-epidemiological situation of the INER resembles global statistics in both diagnosis and personalized treatments.